Missed the Initial Cannabis Boom? Check Out Hot Psychedelic Stock Cybin fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
The Market for Cannabis Companies Continues to Grow and See Rising Sales Numbers as More and More States in the U.S. Legalize Marijuana and for Some Companies, Like Curaleaf, 2021 May Be Better Financially Than Anyone Expected Based on its Most Recent Quarterly Report
Curaleaf (CSE:CURA) (OTCQX:CURLF), showed strong first-quarter earnings. These earnings have put them on track to deliver well-above-consensus numbers for the year. They also beat Curaleaf’s own guidance for full-year revenue ($1.2 billion) and are now expecting $1.3 billion. Analysts believe Curaleaf’s impressive performance is due to a number of factors, one of the most significant being that Curaleaf is an all-encompassing company. Curaleaf has a balance and depth within U.S. markets; they are prepared for federal legalization, and they have a strong balance sheet.
After giving the fund some time to perform, INN spoke with Hawkins again to discuss its movement and the interest investors have shown in psychedelics.
Hawkins remains bullish on the long-term impact of the entire psychedelics industry, particularly the potential benefits of widely available medical products to help growing mental health concerns.
“We’re still very excited about what psychedelics can do and the effect it can have on our entire social ecosystem with respect to curing people or helping people with their mental illnesses,” Hawkins said during the video conversation.
The ETF executive credited the initial wave of excitement surrounding the sector to a massive amount of self-generated interest from retail investors, alongside the generous launch of new companies pursuing the space. “There was a lot of investor interest in getting into this sector pretty early,” he said.